Weiss, Glen J <br/><br/>
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2011 
 - 2997-3004 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-10-3425  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Cell Hypoxia--drug effects<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Models, Biological<br/>Neoplasms--drug therapy<br/>Nitroimidazoles--administration & dosage<br/>Phosphoramide Mustards--administration & dosage<br/>Prodrugs--administration & dosage